COMMONWEALTH OF AUSTRALIA

Patents Act 1952-1969

CONVENTION APPLICATION FOR A PATENT

COMMONWEALTH OF AUSTRALIA

CONVENTION APPLICATION FOR A PATENT

We hereby apply for the grant of a Patent for an invention entitled:

PHARMACEUTICAL AGENT FOR THE TREATMENT OF DIABETES MELLITUS

which is described in the accompanying complete specification. This application is a Convention application and is based on the application numbered P33 26 473 2 for a patent or similar protection made in Federal Republic of Germany on 22nd July 1983.

Our address for service is Messrs. Edwd. Waters & Sons, Patent Attorneys, 50 Queen Street, Melbourne, Victoria, Australia.

DATED this 19th day of July 1984,

HOECHST AKTIEGENESELLSCHAFT

by James Murray

Registered Patent Attorney
COMMONWEALTH OF AUSTRALIA
Patents Act 1952
30717/84
DECLARATION IN SUPPORT OF A CONVENTION APPLICATION UNDER PART XVI. FOR A PATENT.

In support of the Convention application made under Part XVI. of the Patents Act 1952 by HOECHST AKTIENGESELLSCHAFT of 45, Brüningstrasse, D-6230 Frankfurt/Main 80, Federal Republic of Germany for a patent for an invention entitled:
"PHARMACEUTICAL AGENT FOR THE TREATMENT OF DIABETES MELLITUS"

we, Johann-Heinrich Reuter, 4 Bodenheimer Straße, D-6500 Mainz,
Franz Lapice, 2 Sandweg, D-6233 Kelkheim (Taunus);
Federal Republic of Germany

do solemnly and sincerely declare as follows:

1. We are authorized by HOECHST AKTIENGESELLSCHAFT the applicant for the patent to make this declaration on its behalf.

2. The basic application as defined by Section 141 of the Act was made in the Federal Republic of Germany under No.P 33 25 473.2 on July 22, 1983 by HOECHST AKTIENGESELLSCHAFT

3. Ulrich Grau, 17 Zeil, D-6238 Hofheim am Taunus
Federal Republic of Germany

is/are the actual inventor(s) of the invention and the facts upon which HOECHST AKTIENGESELLSCHAFT is entitled to make the application are as follows:
The said HOECHST AKTIENGESELLSCHAFT is the assignee of the said

Ulrich Grau

4. The basic application referred to in paragraph 2 of this Declaration was the first application made in a Convention country in respect of the invention the subject of the application.

DECLARED at Frankfurt/Main, Federal Republic of Germany
this 18th day of June 1984

To the Commissioner of Patents

Hoechst
Aktiengesellschaft

Prokurist
Authorized signatory

PAT 510
(ppa.Reuter) (i.V.Lapice)
**AUSTRALIAN PATENT ABSTRACT**

**AU**

**AU-A-30917/84**

---

**(54)** INSULIN AGENT

**(71)** HOECHST AKTIENGESELLSCHAFT

**(21)** 30917/84 (22) 20.7.84 (24) 22.7.83

**(31)** 3326473 (32) 22.7.83 (33) DE

**(43)** 24.1.85

**(51)** A61K 37/26

**(72)** ULRICH GRAU

**(74)** WM

**(57)** **Claim**

1. A medicament consisting of a physiologically acceptable excipient and an active compound combination, which contains, as the active compound combination, an insulin derivative of the formula I

![Chemical Structure](attachment:image)

in which

- **R**<sub>1</sub> denotes H or H-Phe,
- **R**<sub>30</sub> represents the radical of a neutral L-amino-acid which can be genetically coded and

---
R³¹ represents a physiologically acceptable organic group of basic character with up to 50 carbon atoms, in the build-up of which 0 to 3 L-amino-acids participate and in which the terminal carboxyl function optionally present can be free, as an ester function, as an amide function, as a lactone or reduced to \(\text{CH}_2\text{OH}\), with an isoelectric point between 5.8 and 8.5, and b) an insulin of the formula I in which

- \(R\)

\(R^1\) denotes H or H-Phe,
\(R^{30}\) represents Ala, Thr or Ser and
\(R^{31}\) denotes OH,

or physiologically acceptable salts thereof, and, if appropriate, proinsulin and, if appropriate, C peptide.

Instead of the arginines naturally occurring on B31 or B32.
Name of Applicant: HOECHST AKTIENGESELLSCHAFT

Address of Applicant: 45 Bruningstrasse, D-6230 Frankfurt/Main 80, Federal Republic of Germany

Actual Inventor: ULRICH GRAU

Address for Service: EDWD. WATERS & SONS, 50 QUEEN STREET, MELBOURNE, AUSTRALIA, 3000.

Complete Specification for the invention entitled:

PHARMACEUTICAL AGENT FOR THE TREATMENT OF DIABETES MELLITUS

The following statement is a full description of this invention including the best method of performing it known to us.
Diabetes mellitus is a metabolism disorder which exhibits an increased level of blood sugar as the essential symptom. It is caused by an insufficient amount of the pancreatic hormone insulin being released. At present, the natural hormone is as a rule replaced by animal insulin isolated from the glands of slaughtered animals, or human insulin, which is accessible semisynthetically from porcine insulin or by genetic engineering methods.

Two fundamentally different ways have hitherto been taken in the use of genetic engineering methods: separate synthesis of A and B chains and their subsequent chemical recombination, and synthesis of prepro-insulin, the naturally occurring precursor of insulin.

In the proinsulin molecule, the A and B chain are linked by a connecting piece, the C peptide. According to current theory, the most important function of this piece is spatial fixing of the two chains relative to one another, so that correct folding can take place. When folding has taken place, the three disulfide bridges are linked and the unmodified three-dimensional structure of the insulin is thus stabilized. The C peptide is split off by enzymes having a trypic and carboxypeptidase B activity. The splitting sites are predetermined by a Lys-Arg sequence (before the N-terminus of the A chain) or an Arg-Arg sequence (at the C-terminus of the B chain). Only free insulin has full biological activity, because
part of the biological recognition region on the surface of the molecule is probably masked in the presence of the C peptide.

The particular chemical nature of insulin means that therapy is as a rule parenteral; the hormone would be completely degraded even before it was able to act, for example, on passage through the stomach and intestine. However, degradation reactions, essentially by various, relatively non-specific proteolytic enzymes, also take place at the injection site and in the circulation. The short in vivo half life of only about 7 minutes which thereby results is in principle appropriate from the physiological point of view in the context of homeostasis; however, therapy is thereby made considerably more difficult, because the diabetic must typically inject himself four times daily, as a rule shortly before mealtimes.

Early attempts have accordingly already been made to impart a protracted action to the insulin. The most successful so far have been those methods in which the insulin is converted into a sparingly soluble state by addition of a depot auxiliary. Depot auxiliaries include, above all, divalent zinc ions, in the presence of which the insulin can be in crystalline or amorphous form in a neutral medium. The addition of basic proteins, for example protamine sulfate or human globin, has the same effect, since insulin is an acid molecule with an isoelectric point $p_I$ of 5.4: basic protein and insulin are in the form of a crystalline or amorphous salt-like,
sparingly soluble complex in the neutral range.

It is imagined that the slow release of the insulin from these sustained release formulations takes place by dilution, i.e. diffusion, of individual components which build up the crystal or the amorphous precipitate, or, in the case of insulin complexes with basic proteins, by proteolytic degradation of the depot excipient.

Human proinsulin, either by itself or in combination with the customary depot additives, has recently also been discussed as a delayed action principle (see German Patent A 3,232,036). The theory is that the proteolytic splitting of the C peptide is delayed in vivo and hence the fully active hormone is released from the proinsulin, which has only little inherent biological activity (about 1/8th of the activity of insulin, based on the amount of protein). Only those proinsulins which are identical (there are evidently several) or very similar in their sequence to that from humans are acceptable for use on humans. As is generally known, porcine and bovine proinsulin are immunogenic. The exact mode of action of proinsulin, however, is at present still open. It has in no way been proved that insulin is specifically released. On the contrary, degradation in vivo will take place in several ways, with production of in most cases inactive fragments. The therapeutic use of pro-insulin could thus rather be found, if at all, at the receptor level.

Diabetes therapy is characterized by individual
influence factors, such as differences in the utili-
ability of the meals, differences in the characteristics
of the subcutaneous tissue and also specific eating hab-
its, physical activities and many others besides. It
is thus absolutely essential for good adjustment of
the blood sugar to have available a number of insulin
products with different action characteristics which
are adapted to the individual requirements. In connec-
tion with non-optimum adjustment, in particular the topic
of delayed diabetic damage is discussed, besides the
immediate subjective and objective effects, such as
hyper- or hypoglycemia. This delayed damage includes,
above all, macro- and micro-angiopathy, neuropathy,
nephropathy and retinopathy.

Besides pure delayed action insulins, so-called
intermediate insulins have above all proved to be pre-
parations which are optimally suited to the requirements
of the patient. These are mixtures of a delayed action
component and a component having an immediate and short
action. Such mixtures are in general complicated multi-
phase systems which remain stable over a long period only
when mixed in relatively narrowly defined proportions.
Thus, for example, a suspension of 2-zinc-insulin cry-
stalks from pigs is not freely miscible with dissolved
porcine insulin. The admixed, dissolved insulin precip-
itates immediately or in the course of time because of
the relatively high zinc content which is necessary to
stabilize the crystals. Such mixtures are stable within
narrow limits if bovine insulin (but in this case the

insulin and/or C peptide and insulin derivative of the
formula I can also be used in the form of an alkali metal
calcium or the potassium salt.

- 19 -
specious purity, a medically desirable property, is lost) or a mixture of dissolved porcine insulin and phenylalanine (B1)-porcine insulin is used as the dissolved insulin (German Patent A 2,418,218 and German Patent A-2,459,515). From the point of view of miscibility with dissolved insulin, protamine-insulin formulations are more advantageous, if crystals of protamine and insulin are used in an isophane ratio as the delayed action component. NPH-typical action profiles can be produced with these products; the presence of protamine sulfate, as an exogenous but relatively acceptable protein, appears a suitable additive.

The object of the invention is to provide a stable pharmaceutical agent which has an action characteristic adapted to the individual requirements of the diabetic.

According to the invention, this object has now been achieved by an active compound combination of an insulin derivative, the B chain of which carries a C-terminal organic group of basic character, and an unmodified insulin or its des-Phe31 analog.

Insulin derivatives which carry Arg-OH or Arg-Arg-OH radicals on the C-terminal end of the B chain have already been described. As is known, these derivatives are formed as natural intermediates on enzymatic conversion of proinsulin into insulin in vivo, and small amounts can also be detected in pancreas extracts. The radicals mentioned are usually split off by trypsin and/or carboxypeptidase B or enzymes of similar specificity,
unmodified insulin being released.

More of these insulin derivatives which are base-modified on the C-terminal end, processes for their preparation and their use are the subject of German Patent Application P (HOE 83/F 141).

The invention relates to medicaments consisting of a physiologically acceptable excipient and an active compound combination, which contain, as the active compound combination,

\[ \text{H - Gly A chain Asn} \]

in which

- \( R^1 \) denotes H or H-Phe,
- \( R^{30} \) represents the radical of a neutral L-amino-acid which can be genetically coded and
- \( R^{31} \) represents a physiologically acceptable organic group of basic character with up to 50 carbon atoms, in the build-up of which 0 to 3 \( \alpha \)-amino-acids participate and in which the terminal carboxyl function optionally present can be free, as an ester function, as an amide function, as a lactone or reduced to \( \text{CH}_2\text{OH} \), with an isoelectric point between 5.8 and 8.5, and

protein when the formulation is exposed to heat or mechanical stress on contact with various materials. Such stabilizers are known, for example, from European Patent...
b) an insulin of the formula I

in which

\( R^1 \) denotes \( H \) or \( H\text{-Phe} \),

\( R^{30} \) represents Ala, Thr or Ser and

\( R^{31} \) denotes OH,

or physiologically acceptable salts thereof, and, if appropriate, proinsulin and, if appropriate, C peptide.

Preferred agents are those in which, in the insulin derivative of the formula I, mentioned under a),

\( R^{31} \) represents a radical of the formula \(-X_n-S\),

in which

\( n \) is 0, 1, 2 or 3,

\( X \) represents identical or different radicals of naturally occurring neutral or basic L-amino-

acids (preferably a basic L-aminoacid, in particular Arg, Lys, His or Orn) and/or of D-amino-

acids corresponding to these, and

\( S \) denotes OH or a physiologically acceptable group which blocks the carboxyl group and which,

is 0, carries a positively charged or protonatable basic radical or, if \( n \) is 0, can carry such a radical, and in which the C-terminus \(-X-S\) can also represent the radical of an amino-

acid reduced to the corresponding alcohol or, if \( n \) is 2 or 3, can represent the homoserine-lactone radical.

Particularly preferred insulin derivatives of the formula I are those which carry phenylalanine in position B1. Those which contain Ala, Thr or Ser in position
B30 are also preferred. Their A chain and the (B2-29) chain advantageously have the sequences of bovine or porcine insulin or, in particular, those of human insulin.

The amino acid radicals X and radicals of the corresponding derivatives can be in the D- or L-configuration independently of one another. However, the L-configuration is preferred for all the radicals.

The following L-amino acids can be genetically coded: Gly, Ala, Ser, Thr, Val, Leu, Ile, Asp, Asn, Glu, Gin, Cys, Met, Arg, Lys, His, Tyr, Phe, Trp and Pro (neutral amino acids are underlined).

A neutral, naturally occurring amino acid is understood as meaning, in particular, Gly, Ala, Ser, Thr, Val, Leu, Ile, Asp, Gin, Cys, Met, Tyr, Phe, Pro or Hyp. A basic, naturally occurring amino acid is understood as meaning, in particular, Arg, Lys, His, Orn, Cit or His.

Groups which may block a free carboxyl function on the C-terminal end of the B chain in the insulin derivatives according to the invention are understood as meaning, above all, ester and amide groups, preferably (C1 to C6)-alkoxy, (C3 to C6)-cycloalkoxy, NH2, (C1 to C6)-alkylamino or di-(C1 to C6)-alkylamino, or basic groups, such as amino-(C2 to C6)-alkoxy, (C2 to C4)-alkylamino-(C2 to C4)-alkoxy, di-(C1 to C4)-alkylamino-(C2 to C6)-alkoxy, tri-(C1 to C4)-alkylammonio-(C2 to C6)-alkoxy, amino-(C2 to C6)-alkylamino, (C1 to C6)-alkylamino-(C2 to C4)-alkylamino, di-(C1 to C4)-alkylamino-(C2 to C6)-alkylamino or tri-(C1 to C4)-alkylammonio-(C2 to C6)-alkylamino.
alkylamino, in particular $-O-(CH_2)_p-NR_2$, $-O-(CH_2)_p-NR_3$
$-NH-(CH_2)_p-NR_2$ or $-NH-(CH_2)_p-NR_3$, in which $p$ is 2 to 6 and the radicals $R$ are identical or different and represent hydrogen or $(C_1$ to $C_4)$-alkyl.

The following compounds may be mentioned as examples from the series of insulin derivatives of the formula 1, according to the invention, without limiting the invention to these compounds:

Human insulin-$ArgB_31-OH$

10 Porcine insulin-$ArgB_31-OH$
Bovine insulin-$ArgB_31-OH$
Human insulin-$ArgB_31-ArgB_32-OH$
Porcine insulin-$ArgB_31-ArgB_32-OH$
Bovine insulin-$ArgB_31-ArgB_32-OH$

15 Des-Phe$B_1$-porcine insulin-$ArgB_31-OH$
Des-Phe$B_1$-human insulin-$ArgB_31-OH$
Des-Phe$B_1$-porcine insulin-$ArgB_31-ArgB_32-OH$
Des-Phe$B_1$-human insulin-$ArgB_31-ArgB_32-OH$
Porcine insulin-$ArgB_31-OCH_3$

20 Human insulin-$ArgB_31-OCH_3$
Bovine insulin-$ArgB_31-OCH_3$
Porcine insulin-$ArgB_31-ArgB_32-OCH_3$
Human insulin-$ArgB_31-ArgB_32-OCH_3$
Des-Thr$B_30$-human insulin-$ValB_30-ArgB_32-OCH_3$

25 Des-Thr$B_30$-human insulin-$ValB_30-ArgB_31-OH$
Des-Thr$B_30$-human insulin-$ValB_30-AlaB_31-ArgB_32-OH$
Human insulin-$LysB_31-OH$
Human insulin-$D-ArgB_31-OH$
Human insulin-$D-ArgB_31-ArgB_32-OH$

Human insulin-($B_30$)-choline ester

$7.2 \text{ mg}$

(28 IU/mg)
The insulin derivatives of the formula I are prepared by a process which comprises

a) condensing a des-octapeptide-(G23-SO) insulin of the formula II

or 1 N NaOH.

Such a preparation has a pronounced sustained action in diabetics.
in which $R^1$ denotes Phe or a bond and $S^1$ denotes an amino-protective group which can be split off by proton solvolysis or by β-elimination, such as the tert.-butoxy-carbonyl (Boc), the tert.-amyloxycarbonyl (Aoc) or the methylsulfonylethoxycarbonyl (Msc) radical, with a peptide of the formula III

$$\text{H-Gly-Phe-Phe-Tyr(S}^2\text{-Thr(S}^2\text{-Pro-Lys(S}^3\text{-R}^{30}\text{-R}^{31}\text{)}}\text{)}$$

in which $R^{30}$ and $R^{31}$ have the meanings defined above, $S^2$ represents hydrogen, Bzl or But and $S^3$ represents a urethane-protective group, such as Joc, Moc or Z, any free COOH, OH, SH, $\text{O-NH}_2$, guanidino and/or imidazole groups present on the radicals $R^{30}$ and $R^{31}$ being protected, if necessary, in a manner which is known per se, and, if appropriate, splitting off the protective groups present in a manner which is known per se,

b) reacting, in the presence of trypsin or a trypsin-like endo-peptidase, a des-$B^{30}$-insulin of the formula I in which $R^1$ represents H or H-Phe and the C-terminus $R^{30}$-$R^{31}$ together represents OH, with a compound of the formula IV
in which \( R^{30} \) and \( R^{31} \) have the meanings defined above and in which the free COOH, \( \text{OH} \), \( \text{SH} \), \( \text{ω-NH_2} \), guanidino and/or imidazole functions present are protected, if necessary, in a manner which is known per se, and, if appropriate, subsequently splitting off the protective groups present in a manner which is known per se, or

(c) for the preparation of an insulin derivative with aminoacid radicals in the radical \( R^{31} \) in the L-configuration, chemically and/or enzymatically splitting a pro-insulin, proinsulin analog or preproinsulin analog or an intermediate of these compounds.

The des-B7 insulin used as starting compounds in process variant b) are known, for example from European Patent A-44,979 or Hoppe-Seyler's Z.Physiol. Chem. 359 (1978) 799. The starting material of the formula IV used in variant b) is prepared in a manner which is known per se by the methods of peptide chemistry. Protective groups which can be used for IV are described in detail in M. Bodanzky et al., Peptide Synthesis, 2nd Edition, 1976, Wiley & Sons.

Human or primate proinsulin is meanwhile accessible as the starting material for process variant c) by genetic engineering methods; the derivatives Arg(B31) and di-Arg(B31-32) are accessible therefrom by simple digestion with trypsin or trypsin-like enzymes. However, it is also possible additionally to construct relatively simple plasmids which lead to novel insulin derivatives because they code other neutral or basic aminoacids.

**THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:**
instead of the arginines naturally occurring on B31 or B32.

The preparation of proinsulin using recombinant DNA methodology requires the formation of a DNA sequence which codes the aminoacid sequence of a proinsulin, which can be achieved either by isolation or construction or by a combination of the two. The proinsulin DNA is then inserted into a suitable cloning and expression carrier in the reading phase. The carrier serves to transform a suitable microorganism, and the transformed microorganism thereby obtained is then subjected to fermentation conditions which lead to the formation of further copies of the proinsulin-containing vector and to the expression of the proinsulin of a proinsulin derivative or a proinsulin precursor or a preproinsulin derivative.

If the expression product is a proinsulin precursor, such a product in general contains the proinsulin aminoacid sequence bound at its terminal amino group to a fragment of a protein which is usually expressed by the gene sequence into which the proinsulin or proinsulin derivative has been inserted. The proinsulin aminoacid sequence is bound to the protein fragment via a site which can be split specifically, which is, for example, methionine.

The resulting proinsulin aminoacid sequence is split off from the fused gene product, for example as described in German Patent A-3,232,036, and, after purification, the proinsulin is isolated.

The enzymatic splitting of the proinsulin or

R^31 \text{ denotes } \text{OH},
or physiologically acceptable salts thereof, and, if
proinsulin derivative obtained in this manner is effected by a procedure analogous to that described in Excerpta Medica International Congress Series No. 231, page 292 et seq., or that in German Patent Application P 3,209,184 (HOE 82/F 047).

In addition to the known arginine(B30) and di-arginine(B31-32) derivatives and those derivatives which are accessible by genetic engineering methods and carry naturally occurring L-aminoacids on R31, a number of novel insulin derivatives which have, as a characteristic, one or more basic groups and/or the absence of the free carboxyl group, so that the net charge of the molecule increases by at least one positive charge in comparison with unmodified insulin or in comparison with des-PheB1-insulin, are thus accessible with the aid of the semi-synthetic processes described.

These derivatives include, for example, derivatives which contain at position B-31, instead of the naturally occurring aminoacid L-lysine, L-histidine or L-arginine, their D-enantiomers or the usual D- or L-aminoacid analogs, which carry a basic grouping (for example ornithine or hydroxylysine) in the side chain. Instead of an aminoacid, the choline ester group, for example, may occur at the site of position B31, which means that two net positive charges are obtained. The aminoacid/aminoacid analog at position B31 can have a free carboxyl end or be esterified with simple alcohols (for example methanol or ethanol) or amidated with simple nitrogen bases (for example ammonia or mono- or
di-methylamine); it can also be esterified, for example, with choline. A neutral or another naturally occurring basic amino acid or one of the amino acid derivatives described above, for example, can follow at position B31; in an analogous manner, the carboxyl group thereof can be free or esterified or amidated. In this case also, the choline ester group or another neutral or basic amino acid or an amino acid analog, for example, can follow.

All these insulin derivatives have the common factor that the additional positive charge(s) on the surface of the molecule gives to the molecule an isoelectric point which is shifted into the neutral range. Depending on the derivative, isoelectric points of 5.8 to 8.5, in particular 6.2 to 8.2, are measured on isoelectric focusing. The derivatives are thus less soluble in the neutral range than unmodified insulin or proinsulin, which have their isoelectric point and hence their region of maximum insolubility at pH 5.4, whilst they are usually in solution in the neutral range.

These insulin derivatives of the formula I are accordingly completely novel delayed action principles in which the action can be started without depot auxiliaries, such as zinc or protamine sulfate. The depot action is attributed to an inherent physical principle resulting from protein chemistry, i.e. the sparing solubility at the isoelectric point. Redissolving under physiological conditions, as will be assumed, should be achieved by splitting off the additional basic groups, which is brought about, depending on the derivative, by

- 29 -

10, in which the mixing proportions of unmodified insulin and/or proinsulin and/or des-Phe-insulin and/or peptide and insulin derivative vary in the range from
tryptic or trypsin-like, and/or carboxypeptidase B or carboxypeptidase B-like and/or esterase activity. The particular groups split off are either purely physiological metabolites, such as aminoacids, ornithine or choline, or physiologically acceptable substances which can easily be metabolized.

Porcine insulin-ArgB31-OH and the corresponding diarginine derivative have only 62% and, respectively, 66% of the activity of unmodified porcine insulin, according to the investigations by Chance, Excerpta Medica International Congress Series No. 231, pages 292 and 293.

Surprisingly, it has now been found that (also in contrast to proinsulin) the biological activity of the derivatives is of about the same level as that of unmodified insulin. Also in contrast to the intermediates described in the literature, which still contain parts of the heterologous C peptide, their immunogenic action is no more powerful than that of the corresponding insulin itself. The abovementioned values of Chance, which are too low, are possibly caused by the fact that these peptides were not in pure form or that the measurement had a systematic error.

Besides using the derivatives described, by themselves or as a mixture, as pure delayed action insulins or in combination with the known depot excipients, it is now possible to prepare, in many ways, stable mixtures with insulin which is rapidly available, for example with dissolved contents. A range of very finely adjusted action profiles is thus accessible.
Particularly suitable products are neutral mixtures of one or more derivatives, which act as sustained release components, with dissolved, unmodified insulin, preferably from the same species. In addition, however, it is also possible to use proinsulin and/or C peptide, in each case by itself or in combination with insulin, as the dissolved component. The characteristic of these formulations is that they are stable in all mixing ratios. This is a prerequisite for the preparation of the intermediate active insulin products which are today very common in therapy.

The agents according to the invention can also contain several different insulin derivatives of the formula I and/or several different insulins of the formula I. Moreover, other therapeutically interesting combinations can also be used, such as, for example, a mixture of derivative and insulin and/or proinsulin and/or des-Phe\textsuperscript{B1}—insulin and/or C peptide in dissolved form or in the form of NPH crystals or other conventional delayed action forms. In this manner, products having a very long action and with a different basal profile, inter alia, can be prepared. This would be desirable precisely with human insulin, since, from experience gained so far, its duration of action does not have a true ultra-sustained release profile, as is the case, for example, with the analogous bovine insulin products, either in the form of zinc crystals or in the form of NPH crystals.

The insulin and/or proinsulin and/or des-Phe\textsuperscript{B1}—
insulin and/or C peptide and insulin derivative of the formula I can also be used in the form of an alkali metal salt or the ammonium salt.

The mixing proportions of unmodified insulin and/or proinsulin and/or des-PheB1-insulin and/or C peptide and insulin derivative can vary in the range from 0 to 99% of insulin, and 0 to 99% of proinsulin, and 0-99% of phenylalanine-(B1)-insulin, and 0-99% of C peptide and 1 to 100% of insulin derivative (based on the total amount of these peptides).

An acid solution, for example of the insulin derivative and insulin or proinsulin, which has a pH below the isoelectric point of the insulin is also a use form according to the invention.

Preferred agents have a pH value between 2.5 and 8.5 and are in solution or suspension.

The use forms described are typically dissolved or suspended in an aqueous medium which additionally contains a suitable isotonicity agent, for example glycerol or sodium chloride, and a suitable agent against microbial attack, for example phenol, m-cresol or p-hydroxybenzoic acid ester, in a suitable dosage. This physiologically acceptable excipient can additionally contain, in the pH range from 5.0 to 8.5, a buffer substance, for example sodium acetate, sodium citrate, sodium phosphate or tris-(hydroxymethyl)-aminomethane. Dilute acids, typically hydrochloric acid, or dilute alkalis, typically sodium hydroxide solution, are used for dissolving and for adjustment of the pH value.
The insulin content and/or proinsulin content and/or des-Phe\textsuperscript{B1}—insulin content and/or C peptide content and the content of the insulin derivative of the formula I can, independently of one another, in each case be in dissolved, amorphous and/or crystalline form. In each case any desired part of the insulin content and/or proinsulin content and/or des-Phe—insulin content and/or C peptide content and the content of the insulin derivative of the formula I can be in crystalline form, and in each case any other desired part of the insulin content and/or proinsulin content and/or des-Phe—insulin content and/or C peptide content and the content of the insulin derivative of the formula I can be in amorphous form, and in each case the remainder of the insulin content and/or proinsulin content and/or des-Phe—insulin content and/or C peptide content and of the content of the insulin derivative of the formula I can be in dissolved form.

The formulation can contain suitable amounts of auxiliaries with a delaying action (depot auxiliaries), such as, for example, protamine sulfate, globin or zinc (0 to 100 µg/100 I.U.).

This delayed action principle can be used in combination with the entire active compound content or parts thereof. The formulation can also contain several different auxiliaries having a delaying action.

It is sometimes advantageous to add to the formulation according to the invention a suitable amount of a suitable stabilizer which prevents precipitation of
protein when the formulation is exposed to heat or mechanical stress on contact with various materials. Such stabilizers are known, for example, from European Patent A-18,609, German Patent A-3,240,177 or WO-83/00288.

The following examples serve to further illustrate the invention, without restricting the invention to these.

Example 1

Insulin-Arg^{B31}-Arg^{B32}-OH from pigs, prepared by trypic digestion from porcine proinsulin, in a neutral formulation with 40 IU/ml, and the miscibility thereof with 20% or 40% dissolved porcine insulin (40 IU/ml):

Insulin-Arg^{B31}-Arg^{B32}-OH from pigs 14.8 mg

(27.0 IU/mg)

Sodium dihydrogen phosphate dihydrate 21.0 mg

Glycerol 160.0 mg

Phenol 6.0 mg

m-Cresol 15.0 mg

are dissolved in a total volume of 10 ml with water.

The pH is brought to 7.3 by addition of 1 N HCl or 1 N NaOH. A solution of porcine insulin containing 40 IU/ml in a similar medium or the same medium is mixed in, so that its amount by volume is 20% and 40%. The total content and the content in the supernatant liquor is determined with the aid of HPLC, in each case immediately and after storage at 4°C for 3 months.
<table>
<thead>
<tr>
<th>Total determination</th>
<th>Supernatant liquor</th>
</tr>
</thead>
<tbody>
<tr>
<td>t = 0 3 months</td>
<td>t = 0 3 months</td>
</tr>
<tr>
<td>4°C</td>
<td>4°C</td>
</tr>
<tr>
<td>20%</td>
<td>40 IU/ml</td>
</tr>
<tr>
<td></td>
<td>7.5 IU/ml</td>
</tr>
<tr>
<td>40%</td>
<td>40 IU/ml</td>
</tr>
<tr>
<td></td>
<td>15.6 IU/ml</td>
</tr>
</tbody>
</table>

Porcine insulin-Arg⁸³¹-Arg⁸³²-OH is separated from porcine insulin by HPLC. No derivative can be detected in the supernatant liquor, i.e. the insoluble content is not dissolved. Conversely, after washing the precipitate, no insulin can be detected, i.e. insulin does not precipitate.

**Example 2**

Porcine insulin-Arg⁸³¹-OH, prepared by tryptic digestion from porcine proinsulin, mixed with 25% (activity) of dissolved porcine proinsulin in a neutral formulation with 40 IU/ml, and the depot action thereof:

- **Porcine insulin-Arg⁸³¹-OH**  
  10.9 mg
  
- **Porcine proinsulin**  
  30.3 mg
  
- **Sodium acetate**  
  14.0 mg
- **Methyl p-hydroxybenzoate**  
  10.0 mg
- **Sodium chloride**  
  80.0 mg

are mixed in a total volume of 10 ml with water.

The pH is brought to 7.0 by addition of 1 N HCl or 1 N NaOH.

Such a suspension exhibits a depot action in dogs, which is similar to a comparison depot product.
(Optisulin\textsuperscript{(R)} Depot CS).

\textbf{Example 3}

Porcine insulin-Arg\textsuperscript{B31}-Arg\textsuperscript{B32}-OH, prepared from porcine proinsulin by tryptic digestion, in the form of NPH crystals, mixed with 25\% of des-phenylalanine-(B1)-porcine insulin, prepared from porcine insulin by Edmann degradation, in a neutral formulation with 40 IU/mL, and the delayed action thereof:

Porcine insulin-Arg\textsuperscript{B31}-Arg\textsuperscript{B32}-OH \hspace{1cm} 11.1 mg

27.0 IU/mg

des-Phenylalanine-(B1)-porcine insulin \hspace{1cm} 3.6 mg

28.0 IU/mg

Protamine sulfate \hspace{1cm} 1.0 mg

Sodium dihydrogen phosphate dihydrate \hspace{1cm} 21.0 mg

Phenol \hspace{1cm} 6.0 mg

m-Cresol \hspace{1cm} 16.0 mg

Glycerol \hspace{1cm} 160.0 mg

are mixed in a total volume of 10 mL with water.

The pH is brought to 7.3 by addition of 1 N HCl or 1 N NaOH.

Such a suspension exhibits a depot-like course of action in dogs.

\textbf{Example 4}

Human insulin-(B30)-choline ester, prepared from porcine insulin by semi-synthesis, mixed with 40\% of human insulin and 20\% (by weight) of human C peptide, in a neutral formulation with 40 IU/mL, and the medium-duration action characteristics thereof:
Human insulin-D-Arg\textsuperscript{B31}-OH

Human insulin-D-Arg\textsuperscript{B31}-Arg\textsuperscript{B32}-OH

<table>
<thead>
<tr>
<th>Substance</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Human insulin-(B30)-choline ester</td>
<td>7.2 mg</td>
</tr>
<tr>
<td>(28 IU/mg)</td>
<td></td>
</tr>
<tr>
<td>Human insulin</td>
<td>7.2 mg</td>
</tr>
<tr>
<td>(28 IU/mg)</td>
<td></td>
</tr>
<tr>
<td>Human C peptide</td>
<td>3.6 mg</td>
</tr>
<tr>
<td>Sodium dihydrogen phosphate dihydrate</td>
<td>21.0 mg</td>
</tr>
<tr>
<td>m-Cresol</td>
<td>27.0 mg</td>
</tr>
<tr>
<td>Glycerol</td>
<td>160.0 mg</td>
</tr>
</tbody>
</table>

are mixed in a total volume of 10 ml with water.

The pH value is brought to 7.3 by addition of 1 N HCl or 1 N NaOH.

Such a suspension exhibits an action profile comparable with that of a combination product (for example Komb-H-Insulin\textsuperscript{(R)}, Hoechst), in dogs.

Example 5

Human insulin-Arg\textsuperscript{B31}-Lys\textsuperscript{B32}-OCH\textsubscript{3}, prepared by semi-synthesis from porcine insulin, mixed with 50% of zinc-human insulin crystals in a formulation with 40 IU/ml, and the delayed action thereof:

<table>
<thead>
<tr>
<th>Substance</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Human insulin-Arg\textsuperscript{B31}-Lys\textsuperscript{B32}-OCH\textsubscript{3}</td>
<td>7.4 mg</td>
</tr>
<tr>
<td>(27.0 IU/mg)</td>
<td></td>
</tr>
<tr>
<td>Human insulin</td>
<td>7.4 mg</td>
</tr>
<tr>
<td>(28 IU/mg)</td>
<td></td>
</tr>
<tr>
<td>Zinc chloride, anhydrous</td>
<td>0.23 mg</td>
</tr>
<tr>
<td>Sodium acetate</td>
<td>14.0 mg</td>
</tr>
<tr>
<td>Methyl p-hydroxybenzoate</td>
<td>10.0 mg</td>
</tr>
<tr>
<td>Sodium chloride</td>
<td>80.0 mg</td>
</tr>
</tbody>
</table>

are mixed in a total volume of 10 ml with water.

The pH is brought to 7.0 by addition of 1 N HCl.
or 1 N NaOH.

Such a preparation has a pronounced sustained release action in rabbits (0.4 IU/kg).

Example 6

Human insulin-Arg\textsuperscript{B31}-OH mixed with 30\% of human insulin-Arg\textsuperscript{B31}-Arg\textsuperscript{B32}-OH, both prepared by tryptic digestion from primate proinsulin expressed in E. coli, mixed with 40\% of crystalline NPH-human insulin in a formulation with 40 IU/ml, and the pronounced sustained release action thereof:

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Human insulin-Arg\textsuperscript{B31}-OH</td>
<td>4.4 mg</td>
</tr>
<tr>
<td>(27.5 IU/mg)</td>
<td></td>
</tr>
<tr>
<td>Human insulin-Arg\textsuperscript{B31}-Arg\textsuperscript{B32}-OH</td>
<td>4.4 mg</td>
</tr>
<tr>
<td>(27.0 IU/mg)</td>
<td></td>
</tr>
<tr>
<td>Human insulin</td>
<td>5.7 mg</td>
</tr>
<tr>
<td>(28 IU/mg)</td>
<td></td>
</tr>
<tr>
<td>Protamine sulfate</td>
<td>0.5 mg</td>
</tr>
<tr>
<td>Sodium dihydrogen phosphate dihydrate</td>
<td>21.0 mg</td>
</tr>
<tr>
<td>m-Cresol</td>
<td>15.0 mg</td>
</tr>
<tr>
<td>Phenol</td>
<td>6.0 mg</td>
</tr>
<tr>
<td>Glycerol</td>
<td>160.0 mg</td>
</tr>
</tbody>
</table>

are mixed in a total volume of 10 ml with water.

The pH is brought to 7.3 by addition of 1 N NaOH or 1 N HCl.

Such a suspension exhibits a severely delayed and long-lasting action in rabbits.
CLAIMS
THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:

1. A medicament consisting of a physiologically acceptable excipient and an active compound combination, which contains, as the active compound combination,

   a) an insulin derivative of the formula I

\[ R^1 \text{Val} \, \text{B chain} \]

\[ H - \text{Gly} \, \text{A chain} \, \text{Asn} - \text{OH} \]

in which

- \( R^1 \) denotes H or H-Phe,
- \( R^{30} \) represents the radical of a neutral L-aminoacid which can be genetically coded and
- \( R^{31} \) represents a physiologically acceptable organic group of basic character with up to 50 carbon atoms, in the build-up of which 0 to 3 L-aminoacids participate and in which the terminal carboxyl function optionally present can be free, as an ester function, as an amide function, as a lactone or reduced to CH\(_2\)OH,

with an isoelectric point between 5.8 and 8.5, and

b) an insulin of the formula I

\[ \text{B29} \]

\[ \text{R}^{30} \, \text{R}^{31} \]

in which

- \( R^1 \) denotes H or H-Phe,
- \( R^{30} \) represents Ala, Thr or Ser and
R₃¹ denotes OH, or physiologically acceptable salts thereof, and, if appropriate, proinsulin and, if appropriate, C-peptide.

2. An agent as claimed in claim 1, in which, in the insulin derivative of the formula I, mentioned under a), R₃¹ represents a radical of the formula -Xₙ-S, in which:
   n is 0, 1, 2 or 3,
   X represents identical or different radicals of naturally occurring neutral or basic L-aminoacids and/or of D-aminoacids corresponding to these, and
   S denotes OH or a physiologically acceptable group which blocks the carboxyl group and which, if n is 0, carries a positively charged or protonatable basic radical or, if n is 0, can carry such a radical, and in which the C-terminus -Xₙ-S can also represent the radical of an aminoacid reduced to the corresponding alcohol or, if n is 2 or 3, can represent the homoserine-lactone radical.

3. An agent as claimed in either of claims 1 and 2, in which R¹ represents H-Phe in the insulin derivative and in the insulin of the formula I.

4. An agent as claimed in any one of claims 1 to 3, in which R₃₀ represents Ala, Thr or Ser in the insulin derivative of the formula I, mentioned under 1a).

5. An agent as claimed in any one of claims 1 to 4, in which the aminoacid radicals X are in the L-configuration
in the insulin derivative of the formula I, mentioned under 1a).

6. An agent as claimed in any one of claims 1 to 5, in which S represents OH, (C<sub>1</sub> to C<sub>6</sub>)-alkoxy, (C<sub>3</sub> to C<sub>6</sub>)-cycloalkoxy, NH<sub>2</sub>, di-(C<sub>1</sub> to C<sub>6</sub>)-alkylamino, (C<sub>1</sub> to C<sub>6</sub>)-alkylamino, amino-(C<sub>2</sub> to C<sub>6</sub>)-alkoxy, (C<sub>2</sub> to C<sub>4</sub>)-alkylamino-(C<sub>2</sub> to C<sub>6</sub>)-alkoxy, di-(C<sub>1</sub> to C<sub>4</sub>)-alkylamino-(C<sub>2</sub> to C<sub>6</sub>)-alkoxy, amino-(C<sub>2</sub> to C<sub>6</sub>)-alkylammonio-(C<sub>2</sub> to C<sub>6</sub>)-alkoxy, (C<sub>2</sub> to C<sub>4</sub>)-alkylamino-(C<sub>2</sub> to C<sub>6</sub>)-alkylamino in the insulin derivative of the formula I, mentioned under 1a).

7. An agent as claimed in any one of claims 1 to 6, in which X denotes a radical of a naturally occurring basic aminoacid, such as Lys, Arg, His, Cit, Orn or Hyl and/or the δ-forms thereof, in the insulin derivative of the formula I, mentioned under 1a).

8. An agent as claimed in any one of claims 1 to 7, which contains insulin-B31-Arg-OH or insulin-B31-Arg-Arg-OH.

9. An agent as claimed in any one of claims 1 to 8, which contains several different insulin derivatives of the formula I and/or several different insulins of the formula I.

10. An agent as claimed in any one of claims 1 to 9, which contains proinsulin or proinsulin analogs and/or human C peptide.

11. An agent as claimed in any one of claims 1 to
10. in which the mixing proportions of unmodified insulin and/or proinsulin and/or des-Phe-insulin and/or C peptide and insulin derivative vary in the range from 0 to 99% of insulin, and 0 to 99% of proinsulin, and 0-99% of des-PheB1-insulin, and 0-99% of C peptide and 1 to 100% of insulin derivative of the formula I (based on the total amount of these peptides).

12. An agent as claimed in any one of claims 1 to 11, which has a pH between 2.5 and 8.5 and is in the form of a solution or suspension, and contains a suitable isotonicity agent in the customary amount and a suitable preservative in a suitable amount.

13. An agent as claimed in any one of claims 1 to 12, which additionally contains a suitable amount of a suitable buffer substance, if the pH value is between 5.0 and 8.5.

14. An agent as claimed in any one of claims 1 to 13, wherein the formulation contains a suitable amount of a suitable stabilizer which prevents precipitation of protein on exposure to heat or mechanical stress on contact with various materials.

15. An agent as claimed in any one of claims 1 to 14, which contains a suitable amount of zinc, which can be between 0 and 100 µg/100 units.

16. An agent as claimed in any one of claims 1 to 15, in which the insulin and/or proinsulin and/or des-PheB1-insulin and/or C peptide and insulin derivative of the formula I are used in the form of an alkali metal salt or the ammonium salt.
17. An agent as claimed in any one of claims 1 to 16, wherein the insulin content and/or proinsulin content and/or des-Phe\(^{B1}\)-insulin content and/or C peptide content and the content of insulin derivative of the formula I can in each case be, independently of one another, in dissolved, amorphous and/or crystalline form.

18. An agent as claimed in any one of claims 1 to 17, in which in each case any desired part of the insulin content and/or proinsulin content and/or des-Phe-insulin content and/or C peptide content and of the content of insulin derivative of the formula I is in crystalline form, in each case any other desired part of the insulin content and/or proinsulin content and/or des-Phe-insulin content and/or C peptide content and of the content of the insulin derivative of the formula I is in amorphous form, and in each case the remainder of the insulin content and/or proinsulin content and/or des-Phe-insulin content and/or C peptide content and of the content of the insulin derivative of the formula I is in dissolved form.

19. An agent as claimed in any one of claims 1 to 18, wherein the formulation contains suitable amounts of one of the known auxiliaries having a delaying action.

20. An agent as claimed in claim 19, in which this delayed action principle is used in combination with the entire active compound content or with parts thereof.

21. An agent as claimed in either of claims 19 and 20, which contains insulin and/or proinsulin and/or des-Phe-insulin and/or C peptide and insulin derivative of the formula I in combination with several different
auxiliaries having a delaying action.

22. A process for the preparation of an agent as
claimed in any one of claims 1 to 21, which comprises
bringing the active compound combination into a suitable
form for administration.

23. The use of a medicament as claimed in any one
of claims 1 to 21 for the treatment of diabetes mellitus.

DATED this 19th day of July 1984.

HOECHST AKTIENGESellschaft

EDWD. WATERS & SONS
PATENT ATTORNEYS
50 QUEEN STREET
MELBOURNE, VIC. 3000.